Historic Moment: Cresco Labs CEO Charlie Bachtell emphasized that President Trump's rescheduling of cannabis from Schedule I to Schedule III marks the most consequential moment in U.S. cannabis history, expected to drive legalization and regulation in the industry.
Public Support: With nearly 90% of Americans supporting some form of cannabis legalization and 74% living in states where it is legal, this policy shift is anticipated to better reflect public sentiment and promote relevant legislation.
Industry Impact: The rescheduling opens opportunities for approximately 450,000 individuals working in the regulated cannabis industry by removing unfair tax burdens, enabling companies to reinvest in infrastructure and job growth within their communities.
Foundation for Banking Reform: This policy change lays the groundwork for banking reform and access to U.S. capital markets, signaling alignment between federal policy and the scale and sophistication of the industry, thus promoting further industry development.
CL
$77.73+Infinity%1D
Analyst Views on CL
Wall Street analysts forecast CL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CL is 87.75 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast CL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CL is 87.75 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
6 Hold
1 Sell
Moderate Buy
Current: 79.730
Low
77.00
Averages
87.75
High
95.00
Current: 79.730
Low
77.00
Averages
87.75
High
95.00
Jefferies
Hold
downgrade
$86 -> $85
2025-12-16
New
Reason
Jefferies
Price Target
$86 -> $85
2025-12-16
New
downgrade
Hold
Reason
Jefferies lowered the firm's price target on Colgate-Palmolive to $85 from $86 and keeps a Hold rating on the shares. Comps get easier, retail inventory levels are in a better place, and valuation has pulled back, but Colgate still has some idiosyncratic risks that keeps the firm on the sidelines for now, the analyst tells investors in a research note. The firm noted that consumer perception of oral care has declined this year, and has not yet inflected positively in terms of value, willingness to participate, or favorability.
Argus
Taylor Conrad
Buy
to
Hold
downgrade
2025-12-11
Reason
Argus
Taylor Conrad
Price Target
2025-12-11
downgrade
Buy
to
Hold
Reason
Argus analyst Taylor Conrad downgraded Colgate-Palmolive to Hold from Buy. The firm cites the company's margins having declined due to rising raw material costs and tariff pressure. Argus adds that it would consider returning the stock to its Buy list if volume pressure abated and margins returned to growth, the analyst tells investors in a research note.
Argus
Buy
to
Hold
downgrade
2025-12-11
Reason
Argus
Price Target
2025-12-11
downgrade
Buy
to
Hold
Reason
Argus downgraded Colgate-Palmolive to Hold from Buy.
RBC Capital
Sector Perform -> Outperform
upgrade
$88
2025-12-09
Reason
RBC Capital
Price Target
$88
2025-12-09
upgrade
Sector Perform -> Outperform
Reason
RBC Capital upgraded Colgate-Palmolive to Outperform from Sector Perform with an unchanged price target of $88. The shares have seen pressure as slowing global category growth has weighed on Colgate's prospects, the analyst tells investors in a research note. The firm believes the company's environment in 2026 will remain difficult, but says estimates and expectations are "appropriately low." RBC thinks the stock's setup is favorable as Colgate-Palmolive gets back on track towards its long-term algorithm growth.
About CL
Colgate-Palmolive Company is a growth company. It is focused on Oral Care, Personal Care, Home Care and Pet Nutrition, it sells its products under brands, such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. Its Oral, Personal and Home Care product segment is managed geographically in five segments, such as North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of traditional and e-commerce retailers, wholesalers, distributors, dentists and skin health professionals. Its Pet Nutrition products include specialty pet nutrition products manufactured and marketed by Hill's Pet Nutrition. The customers for Pet Nutrition products are authorized pet supply retailers, veterinarians and e-commerce retailers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
